• Something wrong with this record ?

The Chemical Composition of Achillea wilhelmsii C. Koch and Its Desirable Effects on Hyperglycemia, Inflammatory Mediators and Hypercholesterolemia as Risk Factors for Cardiometabolic Disease

E. Khazneh, P. Hřibová, J. Hošek, P. Suchý, P. Kollár, G. Pražanová, J. Muselík, Z. Hanaková, J. Václavík, M. Miłek, J. Legáth, K. Šmejkal,

. 2016 ; 21 (4) : 404. [pub] 20160325

Language English Country Switzerland

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc17000311

This study was done to identify the content compounds of Achillea wilhelmsii (A. wilhelmsii) and to evaluate its hypoglycemic and anti-hypercholesterolemic activity and effect on inflammatory mediators. The extracts and fractions of A. wilhelmsii were thoroughly analyzed using high performance liquid chromatography (HPLC), and the total content of phenols and flavonoids was determined. The hypoglycemic activity was evaluated in vivo using alloxan-induced diabetic mice. The effect upon inflammatory mediators was evaluated in vitro using the human monocytic leukemia cell line (THP-1). The anti-hypercholesterolemic activity was evaluated in vitro using the 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase assay kit. The water extract (WE)-treated group showed the highest reduction in the fasting blood glucose levels (FBGL). The chloroform fraction (CF) and ethyl acetate fraction (EAF) both showed a significant ability to reduce the secretion of tumor necrosis factor alpha (TNF-α). The EAF, however, also attenuated the levels of matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9). The CF showed the most significant 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) inhibition activity. The five main compounds in the CF were isolated and identified. Out of the five compounds in the CF, 1β,10β-epoxydesacetoxymatricarin (CP1) and leucodin (CP2) showed the highest anti-hypercholesterolemic potential. A molecular docking study provided corresponding results.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17000311
003      
CZ-PrNML
005      
20170119121012.0
007      
ta
008      
170103s2016 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/molecules21040404 $2 doi
024    7_
$a 10.3390/molecules21040404 $2 doi
035    __
$a (PubMed)27023504
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Khazneh, Elian $u Department of Natural Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Palackého tř. 1, Brno 61242, Czech Republic. eliankhazneh@gmail.com.
245    14
$a The Chemical Composition of Achillea wilhelmsii C. Koch and Its Desirable Effects on Hyperglycemia, Inflammatory Mediators and Hypercholesterolemia as Risk Factors for Cardiometabolic Disease / $c E. Khazneh, P. Hřibová, J. Hošek, P. Suchý, P. Kollár, G. Pražanová, J. Muselík, Z. Hanaková, J. Václavík, M. Miłek, J. Legáth, K. Šmejkal,
520    9_
$a This study was done to identify the content compounds of Achillea wilhelmsii (A. wilhelmsii) and to evaluate its hypoglycemic and anti-hypercholesterolemic activity and effect on inflammatory mediators. The extracts and fractions of A. wilhelmsii were thoroughly analyzed using high performance liquid chromatography (HPLC), and the total content of phenols and flavonoids was determined. The hypoglycemic activity was evaluated in vivo using alloxan-induced diabetic mice. The effect upon inflammatory mediators was evaluated in vitro using the human monocytic leukemia cell line (THP-1). The anti-hypercholesterolemic activity was evaluated in vitro using the 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase assay kit. The water extract (WE)-treated group showed the highest reduction in the fasting blood glucose levels (FBGL). The chloroform fraction (CF) and ethyl acetate fraction (EAF) both showed a significant ability to reduce the secretion of tumor necrosis factor alpha (TNF-α). The EAF, however, also attenuated the levels of matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9). The CF showed the most significant 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) inhibition activity. The five main compounds in the CF were isolated and identified. Out of the five compounds in the CF, 1β,10β-epoxydesacetoxymatricarin (CP1) and leucodin (CP2) showed the highest anti-hypercholesterolemic potential. A molecular docking study provided corresponding results.
650    _2
$a řebříček $x chemie $7 D031162
650    _2
$a acylkoenzym A $x chemie $7 D000214
650    _2
$a zvířata $7 D000818
650    _2
$a antioxidancia $x aplikace a dávkování $x chemie $7 D000975
650    _2
$a buněčné linie $7 D002460
650    _2
$a vysokoúčinná kapalinová chromatografie $7 D002851
650    _2
$a experimentální diabetes mellitus $x farmakoterapie $7 D003921
650    _2
$a flavonoidy $x aplikace a dávkování $x chemie $x izolace a purifikace $7 D005419
650    _2
$a lidé $7 D006801
650    _2
$a hypercholesterolemie $x farmakoterapie $7 D006937
650    _2
$a hyperglykemie $x farmakoterapie $7 D006943
650    _2
$a zánět $x farmakoterapie $7 D007249
650    _2
$a mediátory zánětu $x chemie $7 D018836
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední NOD $7 D016688
650    _2
$a simulace molekulového dockingu $7 D062105
650    _2
$a fenoly $x aplikace a dávkování $x chemie $x izolace a purifikace $7 D010636
650    _2
$a rostlinné extrakty $x aplikace a dávkování $x chemie $7 D010936
650    _2
$a rizikové faktory $7 D012307
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hřibová, Petra $u Department of Natural Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Palackého tř. 1, Brno 61242, Czech Republic. cerfpatolog@gmail.com.
700    1_
$a Hošek, Jan $u Department of Molecular Biology and Pharmaceutical Biotechnology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Palackého tř. 1, Brno 61242, Czech Republic. hhosek@gmail.com.
700    1_
$a Suchý, Pavel $u Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Palackého tř. 1, Brno 61242, Czech Republic. suchypa@vfu.cz.
700    1_
$a Kollár, Peter $u Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Palackého tř. 1, Brno 61242, Czech Republic. kollarp@vfu.cz.
700    1_
$a Pražanová, Gabriela $u Department of Human Pharmacology and Toxicology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Palackého tř. 1, Brno 61242, Czech Republic. prazanovag@vfu.cz.
700    1_
$a Muselík, Jan $u Department of Pharmaceutics, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Palackého 1-3, Brno 61242, Czech Republic. muselikj@vfu.cz.
700    1_
$a Hanaková, Zuzana $u Department of Natural Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Palackého tř. 1, Brno 61242, Czech Republic. hanakovaz@vfu.cz.
700    1_
$a Václavík, Jiří $u Department of Natural Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Palackého tř. 1, Brno 61242, Czech Republic. vaclavikj@vfu.cz.
700    1_
$a Miłek, Michał $u Department of Biotechnology and Bioinformatics, Faculty of Chemistry, Rzeszów University of Technology, Powstańców Warszawy 6, Rzeszów 35-959, Poland. mkkmilek@gmail.com.
700    1_
$a Legáth, Jaroslav $u Department of Biotechnology and Bioinformatics, Faculty of Chemistry, Rzeszów University of Technology, Powstańców Warszawy 6, Rzeszów 35-959, Poland. Jaroslav.Legath@uvlf.sk. Department of Pharmacology and Toxicology, The University of Veterinary Medicine and Pharmacy in Košice, Komenského 73, Košice 04181, Slovakia. Jaroslav.Legath@uvlf.sk.
700    1_
$a Šmejkal, Karel $u Department of Natural Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Palackého tř. 1, Brno 61242, Czech Republic. karel.mejkal@post.cz. Department of Molecular Biology and Pharmaceutical Biotechnology, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Palackého tř. 1, Brno 61242, Czech Republic. karel.mejkal@post.cz.
773    0_
$w MED00180394 $t Molecules (Basel, Switzerland) $x 1420-3049 $g Roč. 21, č. 4 (2016), s. 404
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27023504 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20170119121121 $b ABA008
999    __
$a ok $b bmc $g 1179451 $s 960878
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 21 $c 4 $d 404 $e 20160325 $i 1420-3049 $m Molecules $n Molecules $x MED00180394
LZP    __
$a Pubmed-20170103

Find record

Citation metrics

Archiving options